1st Qtrly 17-18 2nd Qtrly 17-18 3rd Qtrly 17-18 4th Qtrly 17-18 31st ANNUAL REPORT 2016-2017
1st Qtrly 16-17 2nd Qtrly 16-17 3rd Qtrly 16-17 4th Qtrly 16-17 30TH ANNUAL REPORT 2015-2016
1st Qtrly 15-16 2nd Qtrly 15-16 3rd Qtrly 15-16 4th Qtrly 15-16 29TH ANNUAL REPORT 2014-2015
1st Qtrly 14-15 2nd Qtrly 14-15 3rd Qtrly 14-15 4th Qtrly 14-15 28TH ANNUAL REPORT 2013-2014
1st Qtrly 13-14 2nd Qtrly 13-14 3rd Qtrly 13-14 4th Qtrly 13-14 27TH ANNUAL REPORT 2012-2013
1st Qtrly 12-13 2nd Qtrly 12-13 3rd Qtrly 12-13 4th Qtrly 12-13 26TH ANNUAL REPORT 2011-2012
1st Qtrly 11-12 2nd Qtrly 11-12 3rd Qtrly 11-12 4th Qtrly 11-12 25TH ANNUAL REPORT 2010-2011

COLINZ LABORATORIES LIMITED
A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai - 400 078.

AUDITED FINANCIAL RESULTS FOR THE YEAR ENDED : 31ST MARCH 2013.

  (Rupees in '000')
    Un -audited  Audited
S. No. Particulars Quarter ended Year Ended Year Ended
    31.03.2013 31.12.2012 31.03.2012 31.03.2013 31.03.2012
PART-I          
1 (a) Income from Operation        
    Gross Sales
17,481
16,927
13,225
76,818
70,455
    Less: Excise Duty
1,280
1,191
1,509
5,282
4,435
  Net Sales
16,201
15,736
11,716
71,536
66,020
  (b) Other Operating Income 
-
323
-
323
-
  Total Income from Operation
16,201
16,059
11,716
71,859
66,020
2 Expenditure
-
-
-
-
-
  (a) Consumption of Materials
3,152
5,178
6,761
21,402
24,418
  (b) Purchase of Goods Traded
1,144
942
937
5,460
3,457
  (c) (Increase)/Decrease in stock in trade
2,434
(897)
(5,021)
1,702
(1,095)
  (d) Staff Cost
5,566
6,709
4,610
25,748
22,545
  (e) Depreciation
659
653
666
2,619
2,599
  (f) Other Expenditure
2,556
2,905
3,292
12,083
11,694
  Total Expenditure
15,511
15,490
11,245
69,014
63,618
3 Profit/Loss from Operation Before Other Income (1-2)
690
569
471
2,845
2,402
4 Other Income/(Loss)
266
53
159
775
369
5 Profit/Loss before Interest & Exceptional items (3+4)
956
622
630
3,620
2,771
6 Interest
467
474
569
2,021
1,893
7 Profit/Loss after Interest but before exceptional items (5-6)
489
148
61
1,599
878
8 Exceptional items 
-
-
-
-
-
9 Profit/Loss before Tax (7-8)
489
148
61
1,599
878
10 Tax Expenses (Provision for Taxation):      Current tax
-
-
-
297
158
    Deffered tax
-
-
-
504
(384)
     
 
11 Net Profit/Loss after Tax (9-10)
489
148
61
798
1,104
12 Paid up Equity Share Capital (Face Value 10/- Per Share)
354,35
354,35
354,35
354,35
354,35
[Net of allotment money in arrears]
13 Reserves Excluding Revaluation Reserves 
-
-
-
8,428
7,630
14 Earning per share (EPS) before extraordinary item (not Annualised)
-
-
-
-
-
  Basic & Diluted
-
-
-
0.17
0.24
PART-II A. PARTICULARS  OF SHAREHOLDING 
 
1 Public Shareholding
 
  i) Number of Shares
29,04,901
29,04,901
29,02,900
29,04,901
29,02,900
  ii) Percentage of shareholding
63.55%
63.55%
63.51%
63.55%
63.51%
2 Promoters and promoter group Shareholding 
 
a) Pledged/Encumbered
 
i) Number of shares
-
-
-
-
-
  ii) Percentage of shares (as a % of the total shareholding of
-
-
-
-
-
  promoter and promoter group)
 
  iii) Percentage of shares (as a% of the total share capital of the company)
-
-
-
-
-
  b) Non-encumbered
 
i) Number of Shares
1,666,099
1,666,099
1668100
1668099
1668100
  ii) Percentage of shares (as a% of the total shareholding
36.45%
36.45%
36.49%
36.45%
36.49%
  of promoter and promoter group)
 
  iii) Percentage of shares (as a % of the total share capital of the company)
100%
100%
100%
100%
100%
 
  B. INVESTORS COMPLAINTS 3 Months ended 31.03.2013
  Pending at Begining of the Quarter  NIL
  Received During the Quarter NIL
  Disposed of During the Quarter NIL
  Remaining at the end of the Quarter NIL

 

STATEMENT OF ASSETS AND LIAB ILITIES (Rupees in '000')
Particulars As at 31.03.2013 As at 31.03.2012
(Audited) (Audited)
A   EQUITY AND LIABILITIES  
1   SHARE HOLDERS FUND  
  a)  Share Capital 35,435 35,435
  b)   Reserves and Surplus 27,148 26,350
  Sub-Total of Shareholders Fund 62,584 61,785
2   NON CURRENT LIABILITIES  
  a) Long term borrowing  22,554 23,918
  b) Deffered tax liability( net) 3,604 3,100
  c) Other  long term liability 147 98
  d) Long term Provision - -
  Sub-Total of Non Current Liabilities 26,305 27,116
3   CURRENT LIABILITIES  
  a) Short term borrowing  - -
  b) Trade payable 4,014 9,217
  c) Other current liabilities 5,652 4,057
  d) Short term provision - -
  Sub-Total of Current Liabilities 9,666 13,274
       
   
Total ( 1+2+3)
98,554 1,02,175
 
B   ASSETS  
1   NON CURRENT ASSETS  
  a) Fixed Assets 39,761 42,361
  b) Non current investments 3,159 3,159
  c) Long term loans and advances  13,543 13,763
  d) Other Non current assets 599 525
  Sub-Total of Non Current Assets 57,062 59,808
2   CURRENT ASSETS  
  a) Inventories 18,606 21,333
  b) Trade receivable 12,717 10,843
  c) Cash and cash equivalents 9,384 9,258
  d) Short term loans and advances 785 933
    Sub-Total of  Current Assets 41,492 42,367
       
   
Total ( 1+2 )
98,554 1,02,175

 

NOTES :-

  1. The above financial results have been taken on record at a meeting of Board of Directors held on 30-05-2013
  2. The Company operates in single segment of manufacture of pharmaceutical formulations. Hence Accounting Standard on segment reporting is not applicable.
  3. Previous period figures have been regrouped wherever required.

 

  For and on behalf of the Board
  M/s. COLINZ LABORATORIES LIMITED
   
Mumbai Dr. L. S. Mani
30.05.2013 Chairman & Managing Director.

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in